Considerations for Biomarker Testing in NSCLC: Gene Panel Size and Reimbursement

EP: 1.Regional Recommendations and Approaches to Biomarker Testing in NSCLC

Now Viewing

EP: 2.Considerations for Biomarker Testing in NSCLC: Gene Panel Size and Reimbursement

EP: 3.How Has Biomarker Testing Impacted Clinical Practice Across Geographic Regions?

EP: 4.Biomarkers for Guiding Treatment in NSCLC: Liquid Biopsy Versus Tissue-Based Testing

EP: 5.Treatment Strategies for Resectable NSCLC in Asia, With a Focus on Stage IB Disease

EP: 6.Is There a Role for Postoperative Radiotherapy in Stage III NSCLC?

EP: 7.The ADAURA Trial: Adjuvant Osimertinib in EGFR+ Resectable NSCLC

EP: 8.Is There a Continued Role for First-Generation TKIs in Resectable NSCLC?

EP: 9.Global Perspectives on Routine Molecular Testing in Postoperative NSCLC

EP: 10.Resectable NSCLC: Is There a Role for Multidisciplinary Care and Neoadjuvant Therapy?

EP: 11.Regional Approaches to Frontline Treatment for EGFR+ Advanced NSCLC

EP: 12.EGFR+ Advanced NSCLC: Review of Bevacizumab-Based Combination Therapy

EP: 13.EGFR+ Advanced NSCLC: Molecular Testing in Patients Resistant to Frontline TKIs

EP: 14.EGFR+ Advanced NSCLC Resistant to Frontline TKIs: Small Cell Transformation and MET Amplification

EP: 15.EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

EP: 16.Future Perspectives in EGFR+ NSCLC

Transcript:

Tony S.K. Mok, MD: You touch on a very interesting point. At ASCO [American Society of Clinical Oncology Annual Meeting] this year, even the United States, the NGS [next-generation sequencing] pickup rate is not over 50%. What’s the NGS testing rate in advanced-stage lung cancer in China? In a big city, and a big center like yours, I imagine that it would be very high. But on average, a lot of patients are in the lesser so-called developed hospitals or state hospitals. Do they also get tested?

Yi-Long Wu, MD, PhD: Yeah. In China, NGS is very popular. But its approved only for the gene or the sister genes or the ADA genes. This means that if you test the genes you can the test only the 10 or the A for the genes. Personally, I like the bigger panel such as more than 100 genes, because we need to know which [INAUDIBLE] harbored the driver gene, and we are also to know the concurrent mutation. With this confirmation, we know how to influence the treatment that should be done with these different labels and the different strategies.

Tony S.K. Mok, MD: In reference to your interest in gene panel size, in Korea, what’s your preference on gene panel size? Do you like the bigger panel of hundreds of genes, or just focusing on the 10 genes that are relevant for non–small cell lung cancer?

Myung-Ju Ahn, MD: In Korea, we use a large panel, including more than 300 genes. One of the challenges is the long turnaround time for NGS. That’s why we don’t routinely use the NGS up front.

Tony S.K. Mok, MD: I see. And Tetsuya, in Japan, do you use the bigger panel? Oncomine is a bigger panel, right?

Tetsuya Mitsudomi, MD, PhD: Yeah, Oncomine has 46 genes, so it’s a midsize panel. That’s a component diagnostic of the many TKIs [tyrosine kinase inhibitors] for lung cancer. Oncomine is the most popular panel in Japan. But Japan has very strict rule in the connection between the testing and the drugs. Oncomine can be the test for some drugs. In another case, in the MET 14 skipping, comparing diagnostic for tepotinib is actually ArcherDX. It’s another panel. We cannot use Oncomine for MET. Also, cobimetinib is a foundational 1. It’s very strange; that’s a rarity.

Tony S.K. Mok, MD: Hold on a second. If I’ve got a patient who’s Oncomine positive for MET 14 skipping, they cannot receive tepotinib or cobimetinib until they have a foundation medicine or actual testing?

Tetsuya Mitsudomi, MD, PhD: Exactly.

Tony S.K. Mok, MD: Isn’t that a waste of resources? This is silly, don’t you think?

Tetsuya Mitsudomi, MD, PhD: I completely agree with you. The regulators here don’t allow us to use these drugs by Oncomine.

Myung-Ju Ahn, MD: It’s a similar situation in Korea.

Tetsuya Mitsudomi, MD, PhD: Really?

Myung-Ju Ahn, MD: The ROS1 FISH [fluorescence in situ hybridization] or NGS that’s ROS1-positive was not reimbursed. The RTP share is the only method to get a reimbursement. It’s very strange.

Tetsuya Mitsudomi, MD, PhD: Yeah, I agree.

Yi-Long Wu, MD, PhD: From the regulatory point of view, maybe we need to use the so-called the company’s [INAUDIBLE]. But in clinical practice, this is not so important. I wonder sometimes about erlotinib. The company diagnosis is the only 1, but in clinical practice, we could test the EGFR in so many panels and methods. We did not let the patient only for [INAUDIBLE] disease. In the near future, the so called a [INAUDIBLE].

Tony S.K. Mok, MD: It’s a little hypocritical. I’m sure that in Japan you can use any EGFR testing used to get the EGFR or TKI. But not with other [INAUDIBLE], right?

Tetsuya Mitsudomi, MD, PhD: No, EGFR is becoming very strict. We have to use the company diagnostic. There are several, but [INAUDIBLE] company.

Tony S.K. Mok, MD: That is interesting.

Transcript edited for clarity.